Gene Switch / Molecular Switch Market - Distribution by Application Area (Management of Treatment Related Toxicity, Regulation of Gene Expression and Other Applications), Type of Target Therapy (CAR T Cell Therapy, Gene Therapy and Other Therapies), Type of Payment Model Employed (Upfront Payments and Milestone Payments), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
The global gene switch / molecular switch market is expected to reach USD 670 million in 2023 anticipated to grow at a CAGR of 11.5% during the forecast period 2023-2035.
In recent years, the field of adoptive cell therapy has experienced substantial advancements, notably through innovative treatments such as CAR T cell therapy, TCR therapy, TIL, and natural killer cell therapy. These approaches have shown promising clinical outcomes, spurring significant interest within the pharmaceutical industry. Notably, the US FDA has approved nearly 30 cell and gene therapy products, while more than 1,200 cell therapies are undergoing evaluation across various clinical development stages. The approval of over five CAR T cell therapies has particularly intensified focus on advancing cellular therapies.
Despite their potential, these therapies come with limitations. Adverse events, including neurotoxicity, cytokine release syndrome (CRS), on-target/off-tumor toxicity, and graft-versus-host disease (GVHD), pose significant challenges. Consequently, the industry is actively exploring tools and methods to address these issues. Attention has centered on safety switches, molecular switches, gene switches, or suicide switch systems. These mechanisms involve regulatory sites within genes capable of controlling the transcription and translation processes, promising enhanced safety profiles for genetically modified cell products in vivo while preserving the host's immune response.
Moreover, extensive analysis of ongoing developments and trends in the gene switch or molecular switch market has been conducted to project the global market opportunity. The growth of this market is expected to closely align with the expansion of the adoptive cell therapy market throughout the forecast period.
Report Coverage
In recent years, the field of adoptive cell therapy has experienced substantial advancements, notably through innovative treatments such as CAR T cell therapy, TCR therapy, TIL, and natural killer cell therapy. These approaches have shown promising clinical outcomes, spurring significant interest within the pharmaceutical industry. Notably, the US FDA has approved nearly 30 cell and gene therapy products, while more than 1,200 cell therapies are undergoing evaluation across various clinical development stages. The approval of over five CAR T cell therapies has particularly intensified focus on advancing cellular therapies.
Despite their potential, these therapies come with limitations. Adverse events, including neurotoxicity, cytokine release syndrome (CRS), on-target/off-tumor toxicity, and graft-versus-host disease (GVHD), pose significant challenges. Consequently, the industry is actively exploring tools and methods to address these issues. Attention has centered on safety switches, molecular switches, gene switches, or suicide switch systems. These mechanisms involve regulatory sites within genes capable of controlling the transcription and translation processes, promising enhanced safety profiles for genetically modified cell products in vivo while preserving the host's immune response.
Moreover, extensive analysis of ongoing developments and trends in the gene switch or molecular switch market has been conducted to project the global market opportunity. The growth of this market is expected to closely align with the expansion of the adoptive cell therapy market throughout the forecast period.
Report Coverage
- An executive summary of the key insights captured in our report. It offers a high-level view on the likely evolution of the gene switch market in the short to mid-term, and long term.
- A general overview of gene switch, highlighting details on its basic components and mechanism of action. Further, it presents detailed information on applications of gene switch. Additionally, it features a discussion on the future prospects within this domain.
- An elaborate analysis of gene switch platforms based on several relevant parameters, such as type of target gene switch, switch activation, type of activator / repressor, application area, target therapies, highest phase of development and target therapeutic area.
- A product competitiveness analysis of the gene switch platforms, based on supplier power (in terms of the experience of the developer) and product competitiveness (in terms of application area, target therapy, highest phase of development and target indication).
- Detailed profiles of the prominent gene switch developers (shortlisted based on proprietary scoring criteria). Each company profile features a brief overview of the company, details related to its gene switch platform portfolio, recent developments and an informed future outlook.
- An analysis of the various collaborations and partnerships inked between stakeholders engaged in this domain, since 2018. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, application area, type of target therapy, type of partner (industry and non-industry), most active players (in terms of number of partnerships inked) and regional distribution (continent and country-wise) of partnership activity.
- Details on the various investments and grants that have been awarded to players focused on gene switch development. It includes a detailed analysis of the funding instances that have taken place during the period 2019 to 2023 (till January), highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.
- A detailed review of peer-reviewed, scientific articles related to research on gene switch on the basis of several relevant parameters, such as year of publication, type of article, most active publisher, emerging focus areas, active affiliated institutes and geography. The chapter also highlights the top journals (in terms of number of articles published and impact factor).
- An insightful analysis of the patents that have been filed / granted related to gene switch, since 2019, taking into consideration several relevant parameters, such as type of patent, publication year, application year, patent jurisdiction, CPC symbols, type of applicant, patent age and leading players (in terms of number of patents filed / granted). It also features a patent benchmarking analysis and a detailed patent characteristics and patent valuation analysis.
- A business model analysis to understand the operational model adopted by the firms developing gene switch platforms, including service centric model and product centric model.
- A comprehensive market forecast analysis, highlighting the likely growth of the gene switch market, till 2035. We have segregated the current and future opportunity based on as application area (management of treatment related toxicity, regulation of gene expression and other applications), type of target therapy (CAR-T cell therapies, gene therapies and other therapies), type of payment model employed (upfront payments and milestone payments), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).
- aceRNA Technologies
- Autolus Therapeutics
- Bellicum Pharmaceuticals
- Cellectis
- Kiromic BioPharma
- panCELLa
- Precigen
- Sana Biotechnology
- Sangamo Therapeutics
1. PREFACE
1.1. Gene Switch Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Emergence of Gene Switch
3.2.1. Basic Components of Gene Switch
3.2.2. Mechanism of Action of Gene Switch
3.2.3. Type of Gene Regulation
3.3. Applications of Gene Switch
3.3.1. Endogenous Gene Regulation
3.3.2. Exogenous Gene Regulation
3.4. Challenges Associated with Gene Switch
3.5. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Gene Switch / Molecular Switch Platforms: Overall Market Landscape
4.2.1. Analysis by Type of Target Gene Switch
4.2.2. Analysis by Switch Activation
4.2.3. Analysis by Type of Activator / Repressor
4.2.4. Analysis by Application Area
4.2.5. Analysis by Type of Target Therapies
4.2.6. Analysis by Highest Phase of Development
4.2.7. Analysis by Target Therapeutic Area
4.3. Gene Switch / Molecular Switch Platform Developers: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Organization
4.3.4. Analysis by Location of Headquarters
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis: Gene Switch Platforms
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. aceRNA Technologies
6.2.1. Company Overview
6.2.2. Gene Switch Platform Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Autolus Therapeutics
6.3.1. Company Overview
6.3.2. Gene Switch Platform Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Bellicum Pharmaceuticals
6.4.1. Company Overview
6.4.2. Gene Switch Platform Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Cellectis
6.5.1. Company Overview
6.5.2. Gene Switch Platform Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Kiromic BioPharma
6.6.1. Company Overview
6.6.2. Gene Switch Platform Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. panCELLa
6.7.1. Company Overview
6.7.2. Gene Switch Platform Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Precigen
6.8.1. Company Overview
6.8.2. Gene Switch Platform Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Sana Biotechnology
6.9.1. Company Overview
6.9.2. Gene Switch Platform Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Sangamo Therapeutics
6.10.1. Company Overview
6.10.2. Gene Switch Platform Portfolio
6.10.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Gene Switch / Molecular Switch Platforms: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Application Area
7.3.4. Analysis by Year of Partnership and Application Area
7.3.5. Analysis by Type of Target Therapy
7.3.6. Analysis by Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Analysis by Geography
7.3.8.1 Intercontinental and Intracontinental Agreements
7.3.8.2 International and Local Agreements
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding
8.3. Gene Switch / Molecular Switch Platforms: Funding and Investments Analysis
8.3.1. Analysis of Instances by Year of Investment
8.3.2. Analysis of Amount Invested by Year of Investment
8.3.3. Analysis of Instances by Type of Funding
8.3.5. Analysis of Amount Invested by Type of Funding
8.3.6. Analysis of Instances by Type of Investor
8.3.7. Most Active Players: Analysis by Number of Instances
8.3.8. Most Active Players: Analysis by Amount Invested
8.3.9. Analysis of Amount Invested by Geography
8.3.9.1. Analysis by Region
8.3.9.2. Analysis by Country
9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Gene Switch / Molecular Switch Platforms: Recent Publications
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Type of Article
9.3.3. Most Active Publishers: Analysis by Number of Publications
9.3.4. Most Popular Journals: Analysis by Number of Publications
9.3.5. Analysis by Journal Impact Factor
9.3.6. Most Popular Journals: Analysis of Journal Impact Factor
9.3.7. Analysis by Key Focus Areas
9.3.8. Analysis by Affiliated Organization of Author
9.3.9. Most Popular Affiliation: Analysis by Number of Publications
9.3.10. Analysis by Geography
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Gene Switch / Molecular Switch Platforms: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents
10.4. Gene Switch / Molecular Switch Platforms: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Gene Switch / Molecular Switch Platforms: Patent Valuation
10.6. Leading Patents: Analysis by Number of Citations
11. BUSINESS MODEL ANALYSIS
11.1. Chapter Overview
11.2. Gene Switch / Molecular Switch Platform Developers: Business Model Analysis
11.2.1. Analysis by Operational Model
11.2.2. Analysis by Service Centric Model
11.2.3. Analysis by Product Centric Model
11.3. Concluding Remarks
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Gene Switch / Molecular Switch Market, 2023-2035
12.3.1. Gene Switch / Molecular Switch Market: Analysis by Application Area, 2023 and 2035
12.3.1.1. Gene Switch Market for Management of Treatment Related Toxicity, 2023-2035
12.3.1.2. Gene Switch Market for Regulation of Gene Expression, 2023-2035
12.3.1.3. Gene Switch Market for Other Applications, 2023-2035
12.3.2. Gene Switch / Molecular Switch Market: Analysis by Type of Target Therapy, 2023 and 2035
12.3.2.1 Gene Switch Market for CAR T Cell Therapy, 2023-2035
12.3.2.2 Gene Switch Market for Gene Therapy, 2023-2035
12.3.2.3 Gene Switch Market for Other Therapies, 2023-2035
12.3.3. Gene Switch / Molecular Switch Market: Analysis by Type of Payment Model Employed, 2023 and 2035
12.3.3.1. Gene Switch Market for Upfront Payments, 2023-2035
12.3.3.2. Gene Switch Market for Milestone Payments, 2023-2035
12.3.4. Gene Switch / Molecular Switch Market: Analysis by Geography, 2023 and 2035
12.3.4.1. Gene Switch Market in North America, 2023-2035
12.3.4.2. Gene Switch Market in Europe, 2023-2035
12.3.4.3. Gene Switch Market in Asia Pacific, 2023-2035
12.3.4.4. Gene Switch Market in Rest of the World, 2023-2035
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Gene Switch Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Emergence of Gene Switch
3.2.1. Basic Components of Gene Switch
3.2.2. Mechanism of Action of Gene Switch
3.2.3. Type of Gene Regulation
3.3. Applications of Gene Switch
3.3.1. Endogenous Gene Regulation
3.3.2. Exogenous Gene Regulation
3.4. Challenges Associated with Gene Switch
3.5. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Gene Switch / Molecular Switch Platforms: Overall Market Landscape
4.2.1. Analysis by Type of Target Gene Switch
4.2.2. Analysis by Switch Activation
4.2.3. Analysis by Type of Activator / Repressor
4.2.4. Analysis by Application Area
4.2.5. Analysis by Type of Target Therapies
4.2.6. Analysis by Highest Phase of Development
4.2.7. Analysis by Target Therapeutic Area
4.3. Gene Switch / Molecular Switch Platform Developers: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Organization
4.3.4. Analysis by Location of Headquarters
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis: Gene Switch Platforms
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. aceRNA Technologies
6.2.1. Company Overview
6.2.2. Gene Switch Platform Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Autolus Therapeutics
6.3.1. Company Overview
6.3.2. Gene Switch Platform Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Bellicum Pharmaceuticals
6.4.1. Company Overview
6.4.2. Gene Switch Platform Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Cellectis
6.5.1. Company Overview
6.5.2. Gene Switch Platform Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Kiromic BioPharma
6.6.1. Company Overview
6.6.2. Gene Switch Platform Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. panCELLa
6.7.1. Company Overview
6.7.2. Gene Switch Platform Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Precigen
6.8.1. Company Overview
6.8.2. Gene Switch Platform Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Sana Biotechnology
6.9.1. Company Overview
6.9.2. Gene Switch Platform Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Sangamo Therapeutics
6.10.1. Company Overview
6.10.2. Gene Switch Platform Portfolio
6.10.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Gene Switch / Molecular Switch Platforms: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Application Area
7.3.4. Analysis by Year of Partnership and Application Area
7.3.5. Analysis by Type of Target Therapy
7.3.6. Analysis by Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Analysis by Geography
7.3.8.1 Intercontinental and Intracontinental Agreements
7.3.8.2 International and Local Agreements
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding
8.3. Gene Switch / Molecular Switch Platforms: Funding and Investments Analysis
8.3.1. Analysis of Instances by Year of Investment
8.3.2. Analysis of Amount Invested by Year of Investment
8.3.3. Analysis of Instances by Type of Funding
8.3.5. Analysis of Amount Invested by Type of Funding
8.3.6. Analysis of Instances by Type of Investor
8.3.7. Most Active Players: Analysis by Number of Instances
8.3.8. Most Active Players: Analysis by Amount Invested
8.3.9. Analysis of Amount Invested by Geography
8.3.9.1. Analysis by Region
8.3.9.2. Analysis by Country
9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Gene Switch / Molecular Switch Platforms: Recent Publications
9.3.1. Analysis by Year of Publication
9.3.2. Analysis by Type of Article
9.3.3. Most Active Publishers: Analysis by Number of Publications
9.3.4. Most Popular Journals: Analysis by Number of Publications
9.3.5. Analysis by Journal Impact Factor
9.3.6. Most Popular Journals: Analysis of Journal Impact Factor
9.3.7. Analysis by Key Focus Areas
9.3.8. Analysis by Affiliated Organization of Author
9.3.9. Most Popular Affiliation: Analysis by Number of Publications
9.3.10. Analysis by Geography
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Gene Switch / Molecular Switch Platforms: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents
10.4. Gene Switch / Molecular Switch Platforms: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Gene Switch / Molecular Switch Platforms: Patent Valuation
10.6. Leading Patents: Analysis by Number of Citations
11. BUSINESS MODEL ANALYSIS
11.1. Chapter Overview
11.2. Gene Switch / Molecular Switch Platform Developers: Business Model Analysis
11.2.1. Analysis by Operational Model
11.2.2. Analysis by Service Centric Model
11.2.3. Analysis by Product Centric Model
11.3. Concluding Remarks
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Gene Switch / Molecular Switch Market, 2023-2035
12.3.1. Gene Switch / Molecular Switch Market: Analysis by Application Area, 2023 and 2035
12.3.1.1. Gene Switch Market for Management of Treatment Related Toxicity, 2023-2035
12.3.1.2. Gene Switch Market for Regulation of Gene Expression, 2023-2035
12.3.1.3. Gene Switch Market for Other Applications, 2023-2035
12.3.2. Gene Switch / Molecular Switch Market: Analysis by Type of Target Therapy, 2023 and 2035
12.3.2.1 Gene Switch Market for CAR T Cell Therapy, 2023-2035
12.3.2.2 Gene Switch Market for Gene Therapy, 2023-2035
12.3.2.3 Gene Switch Market for Other Therapies, 2023-2035
12.3.3. Gene Switch / Molecular Switch Market: Analysis by Type of Payment Model Employed, 2023 and 2035
12.3.3.1. Gene Switch Market for Upfront Payments, 2023-2035
12.3.3.2. Gene Switch Market for Milestone Payments, 2023-2035
12.3.4. Gene Switch / Molecular Switch Market: Analysis by Geography, 2023 and 2035
12.3.4.1. Gene Switch Market in North America, 2023-2035
12.3.4.2. Gene Switch Market in Europe, 2023-2035
12.3.4.3. Gene Switch Market in Asia Pacific, 2023-2035
12.3.4.4. Gene Switch Market in Rest of the World, 2023-2035
13. CONCLUDING REMARKS
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
